查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1450314

心肌肌鈣蛋白市場：現況分析與預測（2023-2030）

Cardiac Troponin Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 154 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計 2023 年至 2030 年，心肌肌鈣蛋白市場的複合年增長率約為 10.2%。心肌肌鈣蛋白是心肌受損時釋放到血液中的一種蛋白質，使其成為診斷心臟病和其他心臟病的重要標記。心臟病、心臟衰竭和心肌梗塞等心血管疾病的流行是心肌肌鈣蛋白市場的關鍵驅動因素。由於這些疾病持續影響全世界很大一部分人口，因此對用於診斷和監測這些疾病的肌鈣蛋白檢測的需求仍然很高。例如，到 2024 年，全球將有約 6.2 億人患有心臟病和循環系統疾病。據估計，全世界每 13 個人中就有 1 人患有心臟或循環系統疾病。此外，技術進步促使了更靈敏、更特異的肌鈣蛋白測量方法的發展。這些進步提高了肌鈣蛋白檢測的準確性和可靠性，支持其在臨床實踐中的採用。此外，隨著人口老化，人們更容易患心血管疾病，從而增加了對包括肌鈣蛋白在內的心臟生物標記測試的需求。

根據環境，市場分為實驗室測試、現場護理（POC）測試。預計實驗室檢測治療類別在預測期內將表現出最高的複合年增長率。基於實驗室的肌鈣蛋白測量通常具有高精度和準確度，使其適合心血管疾病的診斷和監測。醫療保健提供者通常依靠實驗室測試來獲得準確的肌鈣蛋白測量結果，特別是在需要進行系列測試或評估患有複雜醫療狀況的患者時。例如，2021 年推出了 ARCHITECT hsTnI I 20 檢測方法。這種高度靈敏的肌鈣蛋白 I 測量方法具有更高的準確性和靈敏度，可準確診斷和排除心臟病。此外，基於實驗室的測試平台還提供全面的心臟生物標記測試功能，包括肌鈣蛋白測定以及其他相關測試，例如血脂譜、電解質板和心臟成像。

根據適應症，心肌肌鈣蛋白市場分為心肌梗塞、急性冠狀動脈症候群、冠狀動脈心臟病、充血性心臟衰竭等。其中，心肌梗塞領域的市佔率預計較高。儘管預防性心臟病學和心血管治療取得了進展，但心肌梗塞仍然是全世界發病和死亡的主要原因。人口老化、高血壓、糖尿病和肥胖等心血管危險因子的盛行率上升以及生活方式的改變導致心臟病發病率增加，使得肌鈣蛋白在急性心肌梗塞的診斷和治療中發揮重要作用，從而推動了檢測需求。

根據最終用戶，心肌肌鈣蛋白市場分為醫院、診斷中心等。其中，在預測期內，醫院將更多地採用心肌肌鈣蛋白。本院是治療心肌梗塞、心臟衰竭等急性心血管疾病患者的主要場所。這些疾病的盛行率不斷上升，加上人口老化和心血管危險因子的盛行率不斷增加，導致住院患者數量增加，這些地區對肌鈣蛋白檢測的需求也增加。此外，醫院還實施了急性心血管疾病評估和管理的標準化臨床路徑和方案，並將肌鈣蛋白檢測納入常規臨床實踐。遵守實證指引可確保肌鈣蛋白測試的一致和最佳使用，並支持及時診斷、風險分層和治療啟動。

為了更瞭解心肌肌鈣蛋白產業的市場實施情況，將市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、日本、印度、亞太其他地區）和世界其他地區。由於心血管疾病的盛行率不斷上升、醫療專業人員和公眾對心肌肌鈣蛋白的認識不斷提高、先進技術的市場發展以及治療選擇的增加，北美心肌肌鈣蛋白市場將持續成長。例如，根據 CDC 的數據，2019 年，美國每年約有 805,000 人心臟病發作。大約五分之一的心臟病發作者沒有任何症狀，這意味著傷害已經造成，但患者並沒有意識到。

市場主要參與者包括F. Hoffmann-La Roche Ltd.、BIOMERIEUX.、Abbott、Siemens Healthcare Private Limited、Beckman Coulter, Inc、Trinity Biotech、Bio-Techne、PerkinElmer Inc、Bio-Rad Laboratories, Inc、Eurolyser Diagnostica GmbH等

目錄

第一章 市場介紹

  • 市場定義
  • 主要目標
  • 利益相關者
  • 限制

第二章 研究方法或前提條件

  • 調查過程
  • 調查方法
  • 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章 COVID-19 對心肌肌鈣蛋白市場的影響

第六章2020-2030年全球心肌肌鈣蛋白市場收入

第七章市場洞察：依環境分類

  • 臨床檢查
  • 護理點 (POC) 測試

第八章市場洞察：依跡象分類

  • 心肌梗塞
  • 急性冠狀動脈綜合症
  • 冠狀動脈心臟疾病
  • 充血性心力衰竭
  • 其他

第 9 章 市場洞察：依最終用戶分類

  • 醫院
  • 診斷中心
  • 其他

第10章市場洞察：依地區

  • 北美心肌肌鈣蛋白市場
    • 美國
    • 加拿大
    • 其他北美
  • 歐洲心肌肌鈣蛋白市場
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太心肌肌鈣蛋白市場
    • 中國
    • 日本
    • 印度
    • 亞太其他地區
  • 其他地區心肌肌鈣蛋白市場

第十一章心肌肌鈣蛋白市場動態

  • 市場驅動力
  • 市場課題
  • 影響分析

第十二章心肌肌鈣蛋白市場機會

第十三章心肌肌鈣蛋白市場趨勢與見解

第十四章需求面和供給面分析

  • 需求面分析
  • 供給側分析

第十五章價值鏈分析

第十六章價格分析

第17章 競爭場景

  • 競爭格局
    • 波特五力分析

第十八章 公司簡介

  • F. Hoffmann-La Roche Ltd.
  • BIOMERIEUX.
  • Abbott
  • Siemens Healthcare Private Limited
  • Beckman Coulter, Inc
  • Trinity Biotech
  • Bio-Techne
  • PerkinElmer Inc
  • Bio-Rad Laboratories, Inc
  • Eurolyser Diagnostica GmbH

第19章 免責聲明

簡介目錄
Product Code: UMHE212648

The Cardiac troponin market is expected to register a CAGR of approx. 10.2% over the period of 2023-2030. Cardiac troponins are proteins released into the bloodstream when the heart muscle is damaged, making them essential markers for diagnosing heart attacks and other cardiac conditions. The prevalence of cardiovascular diseases, such as heart attacks, heart failure, and myocardial infarctions, is a significant driver of the cardiac troponin market. As these conditions continue to affect a large portion of the population globally, the demand for troponin testing to diagnose and monitor these diseases remains high. For instance, in 2024, There are around 620 million people living with heart and circulatory diseases across the world. Globally it's estimated that 1 in 13 people are living with a heart or circulatory disease. Furthermore, advances in technology have led to the development of more sensitive and specific troponin assays. These advancements improve the accuracy and reliability of troponin testing, driving adoption in clinical practice. Additionally, the aging population is more susceptible to cardiovascular diseases, leading to a higher demand for cardiac biomarker testing, including troponin..

Based on setting, the market is segmented into Laboratory Testing, Point-of-Care (POC) Testing. The laboratory testing therapy category is expected to witness the highest CAGR during the forecast period. Laboratory-based troponin assays typically offer high accuracy and precision, making them well-suited for the diagnosis and monitoring of cardiovascular diseases. Healthcare providers often rely on laboratory testing to obtain precise troponin measurements, especially in cases requiring serial testing or when assessing patients with complex medical conditions. For instance, In 2021, ARCHITECT hsTnI I 20 assay. This high-sensitivity troponin I assay boasts improved precision and sensitivity for accurate heart attack diagnosis and exclusion. Additionally, Laboratory-based testing platforms offer comprehensive capabilities for cardiac biomarker testing, including troponin assays, alongside other relevant tests such as lipid profiles, electrolyte panels, and cardiac imaging..

Based on indication, the cardiac troponin market has been classified as myocardial infarction, acute coronary syndrome, coronary heart disease, congestive heart failure, and others. Among them, the myocardial infarction segment is expected to grow at a higher share in the market. Despite advancements in preventive cardiology and cardiovascular care, heart attacks remain a leading cause of morbidity and mortality globally. The aging population, rising prevalence of cardiovascular risk factors, such as hypertension, diabetes, and obesity, and lifestyle changes contribute to the increasing incidence of heart attacks, driving demand for troponin testing in the diagnosis and management of acute myocardial infarction.

Based on the end-user, the cardiac troponin market has been classified into hospitals, diagnostic centers, others. Among them, the hospitals category is to witness higher adoption of Cardiac Troponin during the forecast period. : Hospitals are the primary settings for managing patients with acute cardiovascular conditions, such as myocardial infarction and heart failure. The rising incidence of these conditions, coupled with population aging and the increasing prevalence of cardiovascular risk factors, leads to higher patient admissions to hospitals, driving demand for troponin testing in these settings. Moreover, Hospitals implement standardized clinical pathways and protocols for the evaluation and management of acute cardiovascular conditions, incorporating troponin testing into routine practice. Adherence to evidence-based guidelines ensures consistent and optimal use of troponin testing, supporting timely diagnosis, risk stratification, and treatment initiation.

For a better understanding of the market adoption of the Cardiac troponin industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America cardiac troponin market is expected to continue to grow in the coming years, driven by the increasing prevalence of cardiovascular disease and growing awareness of cardiac troponin among healthcare professionals and the general population, development of advanced techniques and the rise in treatment option. For instance, in 2019, according to CDC, Every year, about 805,000 people in the United States have a heart attack. About 1 in 5 heart attacks are silent, the damage is done, but the person is not aware of it.

Some of the major players operating in the market include F. Hoffmann-La Roche Ltd., BIOMERIEUX., Abbott, Siemens Healthcare Private Limited, Beckman Coulter, Inc, Trinity Biotech, Bio-Techne, PerkinElmer Inc, Bio-Rad Laboratories, Inc, Eurolyser Diagnostica GmbH.

TABLE OF CONTENTS

1. MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Cardiac Troponin Market
  • 2.2.Research Methodology of the Cardiac Troponin Market
  • 2.4.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE CARDIAC TROPONIN MARKET

6. GLOBAL CARDIAC TROPONIN MARKET REVENUE, 2020-2030F

7. MARKET INSIGHTS BY SETTING

  • 7.1.Laboratory Testing
  • 7.2.Point-of-Care (POC) Testing

8. MARKET INSIGHTS BY INDICATION

  • 8.1.Myocardial Infarction
  • 8.2.Acute Coronary Syndrome
  • 8.3.Coronary heart disease
  • 8.4.Congestive Heart Failure
  • 8.5.Others

9. MARKET INSIGHTS BY END-USERS

  • 9.1.Hospitals
  • 9.2.Diagnostic Centers
  • 9.3.Others

10. MARKET INSIGHTS BY REGION

  • 10.1NORTH AMERICA CARDIAC TROPONIN MARKET
    • 10.1.1.U.S.
    • 10.1.2.Canada
    • 10.1.3.Rest of North America
  • 10.2EUROPE CARDIAC TROPONIN MARKET
    • 10.2.1.Germany
    • 10.2.2.U.K.
    • 10.2.3.France
    • 10.2.4.Italy
    • 10.2.5.Spain
    • 10.2.6.Rest of Europe
  • 10.3ASIA PACIFIC CARDIAC TROPONIN MARKET
    • 10.3.1.China
    • 10.3.2.Japan
    • 10.3.3.India
    • 10.3.4.Rest of Asia-Pacific
  • 10.4REST OF THE WORLD CARDIAC TROPONIN MARKET

11. CARDIAC TROPONIN MARKET DYNAMICS

  • 11.1.Market Drivers
  • 11.2.Market Challenges
  • 11.3.Impact Analysis

12. CARDIAC TROPONIN MARKET OPPORTUNITIES

13. CARDIAC TROPONIN MARKET TRENDS & INSIGHTS

14. DEMAND AND SUPPLY SIDE ANALYSIS

  • 14.1.Demand Side Analysis
  • 14.2.Supply Side Analysis

15. VALUE CHAIN ANALYSIS

16. PRICING ANALYSIS

17. COMPETITIVE SCENARIO

  • 17.1.Competitive Landscape
    • 17.1.1Porter's Five forces analysis

18. COMPANY PROFILED

  • 18.1.F. Hoffmann-La Roche Ltd.
  • 18.2.BIOMERIEUX.
  • 18.3.Abbott
  • 18.4.Siemens Healthcare Private Limited
  • 18.5.Beckman Coulter, Inc
  • 18.6.Trinity Biotech
  • 18.7.Bio-Techne
  • 18.8.PerkinElmer Inc
  • 18.9.Bio-Rad Laboratories, Inc
  • 18.10.Eurolyser Diagnostica GmbH

19. DISCLAIMER